

# Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

## Brilliant Violet 711(TM) anti-human CD3

RRID:AB\_2566036

Type: Antibody

---

### Proper Citation

BioLegend Cat# 300464, RRID:AB\_2566036

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2566036](http://antibodyregistry.org/AB_2566036)

**Proper Citation:** BioLegend Cat# 300464, RRID:AB\_2566036

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Brilliant Violet 711(TM) anti-human CD3

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** Clone UCHT1

**Antibody ID:** AB\_2566036

**Vendor:** BioLegend

**Catalog Number:** 300464

**Alternative Catalog Numbers:** 300463

**Record Creation Time:** 20250820T054150+0000

**Record Last Update:** 20250820T221437+0000

---

### Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD3.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 7 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Chen Y, et al. (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. *Cancer cell*, 42(7), 1268.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. *Cell reports*, 39(2), 110650.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell*, 185(3), 493.

Kfoury Y, et al. (2021) Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. *Cancer cell*, 39(11), 1464.

Dupraz L, et al. (2021) Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal ?? T cells. *Cell reports*, 36(1), 109332.

Litchfield K, et al. (2021) Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. *Cell*, 184(3), 596.

Berezhnoy A, et al. (2020) Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. *Cell reports. Medicine*, 1(9), 100163.